With its 2-star rating, we believe Lilly stock is overvalued compared with our long-term fair value estimate of $650 per ...

Biogen’s lack of insider buying and reduced R&D spending raise concerns, but its future growth prospects remain. Find out why ...

Rios has been participating in a clinical trial conducted by Washington University in St. Louis in which he has been ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the ...

A phase I/II trial showed that transplanting dopaminergic progenitors derived from induced pluripotent stem cells was safe in ...

Leqembi has been approved in the European Union for the treatment of certain adults with early Alzheimer's disease and mild ...

The Trump administration is expected to announce tariffs on pharmaceuticals "in the next month or two," an official said. | The Trump administration is expected to announce tariffs on pharmaceuticals ...

An experimental treatment appears to delay Alzheimer’s symptoms in some people genetically destined to get the disease in their 40s or 50s, according to new findings from ongoing research now caught ...

On Monday, 74-year-old Ralph Carmona of Portland will be the only qualified Boston Marathon runner with Alzheimer's.

Patients will lose access to cheaper versions of the blockbuster drugs after the agency shuts down the multibillion-dollar industry now that the drug shortage has ended. Also in the news: Eli Lilly's ...

Current health news highlights include the impact of U.S.-China trade tensions on pharmaceutical costs, the World Health ...

Find insight on Abbott Laboratories, Sartorius and more in the latest Market Talks covering the Health Care sector.